Kenvue Inc. · NYSE:KVUE
Kenvue — Q1 2025 Earnings Presentation
32 slides from Kenvue's earnings presentation, May 8, 2025
Slide 1: First Quarter 2025 Earnings Results
First Quarter 2025 Earnings Results May 8, 2025 K€ kenvue
Slide 2: Introduction
Introduction Thibaut Mongon Paul Ruh Sofya Tsinis Chief Executive Officer Chief Financial Officer Vice President of Investor Relations B€ kenvue
Slide 3: Cautionary note on forward-looking statements
Cautionary note on forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements about management’s expectations of Kenvue’s future operating and financial performance, p
Slide 4: Q1 2025 Overview
Q1 2025 Overview ‘S) Delivered Q1 results while navigating dynamic C6) Leveraged Kenvue’s Five Extraordinary Powers environment . . " SC) ot Fae eeetion pa tpaced Organic sales" across Ss) Completed exit of 2,300+ transition services ‘S) Maintained Organic sales! growth outlook for Consolidated U.S.
Slide 5: Q1 2025 By the Numbers
Q1 2025 By the Numbers ©) Strong on pain, (1 . 2) % easy to swallow. When it . . sticks better, y/y Organic sales" it works better. ©) 60.0% Adjusted gross profit margin’ ©) $0.24 Adjusted diluted earnings per share! Works We FAST a” Rich water S On track to deliver | LASTS ; ccalent, $350M ; . 24 h
Slide 6: Q1 2025 Portfolio Performance
Q1 2025 Portfolio Performance Total Kenvue Self Care Q12025 Net Sales Organic Sales” $3.7B $1.7B Q12025 (1.2)% +0.3% Takeaways + Consumption outpaced Organic sales" across all segments due to destocking in Asia and strategic price investments in the U.S. + Driving share gains across the portfolio +
Slide 7: Self Care
Self Care Driving share gains across the portfolio +0.3% Q1 Organic sales” ¢ Broad-based growth across Allergy, Digestive Health, and Smoking Cessation, offset decline in Cold, Cough and Flu ¢ Expanding or maintaining market share across ~80% of the business, enhancing global leadership positions Cu
Slide 8: Skin Health & Beauty
Skin Health & Beauty | (4.8)% Ay Rates Q1 Organic sales” 60 secs * Strategic price investments and loss of club channel rotations in the U.S., destocking in China, and soft sun season in LATAM impacted sales ¢ Strengthening consumption in the U.S. as strategic price and break-through marketing inves
Slide 9: Driving Stronger Consumption Performance in Q1
Driving Stronger Consumption Performance in Q1 Neutrogena Face Aveeno Body OGX Hair LS2WK L26WK LI83WK L4WK LS2WK =L26WK = LISWK = L4WK Ss LS2WK = L26WK = LISWK = LAWK, Source: Edge POS data through 4/27/25 Ne / K€ kenvue 9
Slide 10: Essential Health
Essential Health Flat Q1 Organic sales” * Growth in Wound Care offset by declines in Women’s Health and Oral Care ¢ Driving premiumization to gain distribution and increase household penetration ¢ Bringing additional entry-price point offerings, and implementing strategic price and trade investments
Slide 11: Q1 2025 Financial Performance
Q1 2025 Financial Performance
Slide 12: Reported Net Sales & Organic Sales
Reported Net Sales & Organic Sales” (1.2)% Organic Sales’ Decline in Q1 2025 (— >) $3.9B (0.3%) (0.9%) (2.7%) $3.7B Q12024 Value Volume Foreign Q12025 Net Sales Realization? Exchange Net Sales XX vA K€ kenvue ‘Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures includ
Slide 13: Self Care
Self Care $1.7B Net Sales Organic Sales” Reported (1 .8) % sae tion? +0.3% Organic +0.3% Volume Flat ‘Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules to this presentation and to the earnings release available at investors.kenvue.
Slide 14: Skin Health & Beauty
Skin Health & Beauty $1.0B Net Sales Reported (7.3)% Realization? (1 .I)% sacs’ = (4.8)% Yr? (2.9)% Organic Sales” "Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules to this presentation and to the earnings release available at inv
Slide 15: Essential Health
Essential Health $1.1B Net Sales Organic Sales” Reported (3.9) % Realization? +0.1 % Sales Flat ““™ (0.1)% X ‘Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules to this presentation and to the earnings release available at investors
Slide 16: Adjusted Gross Profit and Operating Income Margins
Adjusted Gross Profit and Operating Income Margins! Adjusted Gross Profit Margin’ 60.2% “20bpsv/y — 60.0% Adjusted Operating Ne Income Margin’ K€ kenvue Key Drivers 6) Strong productivity and continued supply chain efficiencies more than offset by volume deleverage, currency and inflationary headwin
Slide 17: Q1 2025 Net Income and Diluted Earnings Per Share
Q1 2025 Net Income and Diluted Earnings Per Share $0.17 $465M Reported $547M $296M $322M $0.2 4 Adjusted! Q1 2024 Q12025 Q12024 Q12025 N Taw J \ 7 Kenvue ‘Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules to this presentation and t
Slide 18: 2025 Outlook
2025 Outlook Reported Net ° . 5 . > Sales Growth 1% -3% Assumes ~1% currency headwind (1)% -1% Organic Sales! re B Growth 2% - 4% 2% - 4% Adjusted Operating . . . . . Income Margin! Decline y/y Updated for estimated impact of tariffs as of May 7, 2025 Expand y/y Interest Expense, Net Flat y/y Flat y
Slide 19: Thibaut Mongon, Paul Ruh, Sofya Tsinis
Thibaut Mongon Paul Ruh Sofya Tsinis Chief Executive Officer Chief Financial Officer Vice President of Investor Relations B€ kenvue
Slide 20: Kenvue
I€ kenvue
Slide 21: Appendix
Appendix
Slide 22: Organic Sales Change (Non-GAAP)
Organic Sales Change (Non-GAAP) Fiscal Three Months Ended March 30, 2025 vs March 31, 2024 Organic sales change (Unaudited) Sckechange ""PSureancy’ 2" “°dNestitures’” _selesehangs __Price/Mixt Volume Self Care (1.8) % (2.1) % —% 0.3 % 0.3 % — % Skin Health and Beauty (7.3) (2.3) (0.2) (4.8) (1.9) (2
Slide 23: Total Segment Net Sales
Total Segment Net Sales Net Sales Fiscal Three Months Ended (Unaudited; Dollars in Millions) March 30, 2025 March 31, 2024 Self Care $ 1,667 $ 1,698 Skin Health and Beauty 977 1,054 Essential Health 1,097 K€ kenvue 23
Slide 24: Total Segment Adjusted Operating Income
Total Segment Adjusted Operating Income Adjusted Operating Income Fiscal Three Months Ended (Unaudited; Dollars in Millions) March 30, 2025. March 31, 2024 Self Care Adjusted operating income $ 566 $ 601 Skin Health and Beauty Adjusted operating income 92 146 Essential Health Adjusted operating inco
Slide 25: Fiscal Three Months Ended March 30, 2025
Fiscal Three Months Ended March 30, 2025
Slide 26: Non-GAAP Reconciliations (Q1 2024)
Non-GAAP Reconciliations (QV’2024) (Unaudited; Dollars in Net sales jons) Gross profit Gross profit margin Operating income Operating income margin Net income Net income margin Interest expense, net Provision for taxes Depreciation and amortization EBITDA (non-GAAP) EBITDA margin (non-GAAP) Detail o
Slide 27: Adjusted Effective Tax Rate
Adjusted Effective Tax Rate Fiscal Three Months Ended (Unaudited) March 30, 2025 March 31, 2024 Effective tax rate 29.7 % 30.7 % Adjustments: Tax-effect on special item adjustments (2.4) (3.1) Taxes related to Deferred Markets 0.2 K€ kenvue 2
Slide 28: Adjusted Effective Tax Rate
Adjusted Effective Tax Rate Fiscal Year 2025 (Unaudited) Forecast Effective tax rate 28.5% - 29.5% Adjustments: Tax-effect on special item adjustments (3.2) Taxes related to Deferred Markets K€ kenvue 28
Slide 29: Adjusted Diluted Earnings Per Share
Adjusted Diluted Earnings Per Share Fiscal Three Months Ended (Unaudited) March 30, 2025 March 31, 2024 Diluted earnings per share $ 017 $ 0.15 Adjustments: Separation-related costs 0.02 0.03 Restructuring expenses and operating model optimization initiatives 0.03 0.03 Impairment charges - 0.04 Amor
Slide 30: Research and Development
Research and Development (Unaudited; Dollars in Millions) Research & Development K€ kenvue Fiscal Three Months Ended March 30, 2025 March 31, 2024 99 $ 100 30
Slide 31: 2025 Guidance Non-GAAP Reconciliations
2025 Guidance Non-GAAP Reconciliations Kenvue is not able to provide the most directly comparable GAAP measures or reconcile Adjusted diluted earnings per share or Adjusted operating income to comparable GAAP measures on a forward-looking basis without unreasonable efforts given the unpredictability
Slide 32: Kenvue
B€ Kenvue